Molecular mechanisms of intensive care unit-acquired weakness

European Respiratory Journal

Volumn 39, Issue 4, 2012, Pages 1000-1011

  Bloch, S ^a,b   Polkey, M I ^b   Griffiths, M ^b   Kemp, P ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Critical illness; Intensive care unit acquired weakness; Muscle wasting

Indexed keywords

CALPAIN; CASPASE; GLUTAMINE; MUSCLE PROTEIN; MYOSTATIN; NITRIC OXIDE SYNTHASE; SOMATOMEDIN C;

BIOENERGY; CELL STRUCTURE; CRITICAL ILLNESS; DOWN REGULATION; ELECTRICAL INEXCITABILITY; FORCE GENERATING CAPACITY; GLYCEMIC CONTROL; HUMAN; IMMOBILIZATION; INTENSIVE CARE UNIT ACQUIRED WEAKNESS; MOLECULAR PATHOLOGY; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE WEAKNESS; MUSCULOSKELETAL SYSTEM PARAMETERS; MYOFILAMENT; NERVE CONDUCTION; NEUROMUSCULAR FUNCTION; NEUROPATHY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS REGULATION; REVIEW; RISK FACTOR; SARCOPLASMIC RETICULUM; UPREGULATION;

CRITICAL ILLNESS; ENERGY METABOLISM; HUMANS; INTENSIVE CARE UNITS; MUSCLE PROTEINS; MUSCLE WEAKNESS; RISK FACTORS;

EID: 84860331340     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00090011     Document Type: Review

References (156)

1. Fletcher S, Kennedy D, Ghosh I, et al. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 2003; 31: 1012-1016. (Pubitemid 36444406)
2. De Jonghe B, Sharshar T, Lefaucheur J, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002; 288: 2859-2867. (Pubitemid 35425072)
3. De Jonghe B, Bastuji-Garin S, Sharshar T, et al. Does ICU-acquired paresis lengthen weaning from mechanical ventilation? Intensive Care Med 2004; 30: 1117-1121. (Pubitemid 38833364)
4. Ali N, O'Brien JJ, Hoffmann S, et al. Acquired weakness, handgrip strength, and mortality in critically ill patients. Am J Respir Crit Care Med 2008; 178: 261-268.
5. Tennilä A, Salmi T, Pettilä V, et al. Early signs of critical illness polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis. Intensive Care Med 2000; 26: 1360-1363.
6. Surviving Sepsis Campaign. About Sepsis. www.survivingsepsis.org/ Introduction/Pages/default.aspx Date last accessed: August 2011.
7. Hospital Episode Statistics. Adult Critical Care Data. http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID= 1937&categoryID=1298 Date last accessed: August 2011.
8. Subbe C, Criner G, Baudouin S. Weaning units: lessons from North America? Anaesthesia 2007; 62: 374-380. (Pubitemid 46487248)
9. Witt N, Zochodne D, Bolton C, et al. Peripheral nerve function in sepsis and multiple organ failure. Chest 1991; 99: 176-184.
10. Stevens R, Dowdy D, Michaels R, et al. Neuromuscular dysfunction acquired in critical illness: a systematic review. Intensive Care Med 2007; 33: 1876-1891. (Pubitemid 47632264)
11. Eikermann M, Koch G, Gerwig M, et al. Muscle force and fatigue in patients with sepsis and multiorgan failure. Intensive Care Med 2006; 32: 251-259. (Pubitemid 43251146)
12. Ochala J, Ahlbeck K, Radell PJ, et al. Factors underlying the early limb muscle weakness in acute quadriplegic myopathy using an experimental ICU porcine model. PLoS One 2011; 6: e20876.
13. Lacomis D, Zochodne D, Bird S. Critical illness myopathy. Muscle Nerve 2000; 23: 1785-1788.
14. Sander H, Golden M, Danon M. Quadriplegic areflexic ICU illness: selective thick filament loss and normal nerve histology. Muscle Nerve 2002; 26: 499-505.
15. Larsson L, Li X, Edstrom L, et al. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels. Crit Care Med 2000; 28: 34-45. (Pubitemid 30091026)
16. Sher JH, Shafiq SA, Schutta HS. Acute myopathy with selective lysis of myosin-filaments. Neurology 1979; 29: 100-106. (Pubitemid 9051196)
17. Khan J, Harrison T, Rich M. Mechanisms of neuromuscular dysfunction in critical illness. Crit Care Clin 2008; 24: 165-177. (Pubitemid 351172686)
18. Friedrich O. Critical illness myopathy: sepsis-mediated failure of the peripheral nervous system. Eur J Anaesthesiol Suppl 2008; 42: 73-82. (Pubitemid 351643052)
19. Giger JM, Haddad F, Qin AX, et al. Effect of unloading on type I myosin heavy chain gene regulation in rat soleus muscle. J Appl Physiol 2005; 98: 1185-1194. (Pubitemid 40396488)
20. Diaz NL, Finol HJ, Torres SH, et al. Histochemical and ultrastructural study of skeletal muscle in patients with sepsis and multiple organ failure syndrome (MOFS). Histol Histopathol 1998; 13: 121-128. (Pubitemid 28044605)
21. Goldberg AL. Protein turnover in skeletal muscle. II. Effects of denervation and cortisone on protein catabolism in skeletal muscle. J Biol Chem 1969; 244: 3223-3229.
22. Lecker SH. Ubiquitin-protein ligases in muscle wasting: multiple parallel pathways? Curr Opin Clin Nutr Metab Care 2003; 6: 271-275. (Pubitemid 40684602)
23. Gomes MD, Lecker SH, Jagoe RT, et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 2001; 98: 14440-14445. (Pubitemid 33121410)
24. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294: 1704-1708. (Pubitemid 33104839)
25. Ochala J, Gustafson AM, Llano Diez M, et al. Preferential skeletal muscle myosin loss in response to mechanical silencing in a novel rat intensive care unit model: underlying mechanisms. J Physiol 2011; 589: 2007-2026.
26. Ikemoto M, Nikawa T, Takeda S, et al. Space shuttle flight (STS-90) enhances degradation of rat myosin heavy chain in association with activation of ubiquitin-proteasome pathway. FASEB J 2001; 15: 1279-1281.
27. Li YP, Reid MB. NF-κB mediates the protein loss induced by TNF-α in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1165-R1170.
28. Zhang P, Chen X, Fan M. Signaling mechanisms involved in disuse muscle atrophy. Med Hypotheses 2007; 69: 310-321. (Pubitemid 46818689)
29. Cai D, Frantz JD, Tawa NE, et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell 2004; 119: 285-298. (Pubitemid 39360909)
30. Hunter RB, Stevenson E, Koncarevic A, et al. Activation of an alternative NF-κB pathway in skeletal muscle during disuse atrophy. FASEB J 2002; 16: 529-538. (Pubitemid 34273236)
31. Wray CJ, Mammen JM, Hershko DD, et al. Sepsis upregulates the gene expression of multiple ubiquitin ligases in skeletal muscle. Int J Biochem Cell Biol 2003; 35: 698-705. (Pubitemid 36369517)
32. Combaret L, Taillandier D, Dardevet D, et al. Glucocorticoids regulate mRNA levels for subunits of the 19 S regulatory complex of the 26 S proteasome in fast-twitch skeletal muscles. Biochem J 2004; 378: 239-246. (Pubitemid 38299563)
33. Helliwell TR, Wilkinson A, Griffiths RD, et al. Muscle fibre atrophy in critically ill patients is associated with the loss of myosin filaments and the presence of lysosomal enzymes and ubiquitin. Neuropathol Appl Neurobiol 1998; 24: 507-517. (Pubitemid 29002282)
34. Tiao G, Hobler S, Wang JJ, et al. Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J Clin Invest 1997; 99: 163-168. (Pubitemid 27053458)
35. Klaude M, Fredriksson K, Tjader I, et al. Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis. Clin Sci (Lond) 2007; 112: 499-506. (Pubitemid 46762011)
36. Thomas M, Langley B, Berry C, et al. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem 2000; 275: 40235-40243. (Pubitemid 32064654)
37. McFarlane C, Plummer E, Thomas M, et al. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism. J Cell Physiol 2006; 209: 501-514. (Pubitemid 44484641)
38. Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004; 350: 2682-2688. (Pubitemid 38788003)
39. Lenk K, Schur R, Linke A, et al. Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur J Heart Fail 2009; 11: 342-348.
40. Liu CM, Yang Z, Liu CW, et al. Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice. Gene Ther 2008; 15: 155-160. (Pubitemid 351150039)
41. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, et al. Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci USA 1998; 95: 14938-14943. (Pubitemid 29003735)
42. Ma K, Mallidis C, Bhasin S, et al. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 2003; 285: E363-E371. (Pubitemid 36899710)
43. Man WD-C, Natanek SA, Riddoch-Contreras J, et al. Quadriceps myostatin expression in COPD. Eur Respir J 2010; 36: 686-688.
44. Ruff RL, Secrist D. Inhibitors of prostaglandin synthesis or cathepsin B prevent muscle wasting due to sepsis in the rat. J Clin Invest 1984; 73: 1483-1486. (Pubitemid 14139544)
45. Petersson B, Wernerman J, Waller SO, et al. Elective abdominal surgery depresses muscle protein synthesis and increases subjective fatigue: effects lasting more than 30 days. Br J Surg 1990; 77: 796-800. (Pubitemid 20236124)
46. Essen P, McNurlan MA, Gamrin L, et al. Tissue protein synthesis rates in critically ill patients. Crit Care Med 1998; 26: 92-100. (Pubitemid 28028446)
47. Gamrin L, Essen P, Hultman E, et al. Protein-sparing effect in skeletal muscle of growth hormone treatment in critically ill patients. Ann Surg 2000; 231: 577-586. (Pubitemid 30185866)
48. Lang CH, Frost RA. Role of growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins in the catabolic response to injury and infection. Curr Opin Clin Nutr Metab Care 2002; 5: 271-279. (Pubitemid 40684672)
49. Lang CH, Frost RA, Nairn AC, et al. TNF- a impairs heart and skeletal muscle protein synthesis by altering translation initiation. Am J Physiol Endocrinol Metab 2002; 282: E336-E347. (Pubitemid 34654804)
50. Hornberger TA, Hunter RB, Kandarian SC, et al. Regulation of translation factors during hindlimb unloading and denervation of skeletal muscle in rats. Am J Physiol Cell Physiol 2001; 281: C179-C187.
51. Vesali RF, Cibicek N, Jakobsson T, et al. Protein metabolism in leg muscle following an endotoxin injection in healthy volunteers. Clin Sci (Lond) 2010; 118: 421-427.
52. Otto A, Patel K. Signalling and the control of skeletal muscle size. Exp Cell Res 2010; 316: 3059-3066.
53. Bodine SC, Stitt TN, Gonzalez M, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001; 3: 1014-1019. (Pubitemid 34428747)
54. Glass DJ. Molecular mechanisms modulating muscle mass. Trends Mol Med 2003; 9: 344-350. (Pubitemid 37040030)
55. Sacheck JM, Ohtsuka A, McLary SC, et al. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab 2004; 287: E591-E601. (Pubitemid 39242684)
56. Stitt TN, Drujan D, Clarke BA, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004; 14: 395-403. (Pubitemid 38591410)
57. Lin MC, Leung SY, Fang WF, et al. Down-regulation of insulin-like growth factor I (IGF-I) in the mouse diaphragm during sepsis. Chang Gung Med J 2010; 33: 501-508.
58. Nystrom G, Pruznak A, Huber D, et al. Local insulin-like growth factor I prevents sepsis-induced muscle atrophy. Metabolism 2009; 58: 787-797.
59. Lang CH, Frost RA. Sepsis-induced suppression of skeletal muscle translation initiation mediated by tumor necrosis factor a. Metabolism 2007; 56: 49-57. (Pubitemid 44855012)
60. Crossland H, Constantin-Teodosiu D, Gardiner SM, et al. A potential role for Akt/FOXO signalling in both protein loss and the impairment of muscle carbohydrate oxidation during sepsis in rodent skeletal muscle. J Physiol 2008; 586: 5589-5600.
61. West DW, Burd NA, Staples AW, et al. Human exercise-mediated skeletal muscle hypertrophy is an intrinsic process. Int J Biochem Cell Biol 2010; 42: 1371-1375.
62. Sharshar TS, Bastuji-Garin B, De Jonghe RD, et al. Hormonal status and ICU-acquired paresis in critically ill patients. Intensive Care Med 2010; 36: 1318-1326.
63. Glover EI, Phillips SM, Oates BR, et al. Immobilization induces anabolic resistance in human myofibrillar protein synthesis with low and high dose amino acid infusion. J Physiol 2008; 586: 6049-6061.
64. Rennie MJ. Anabolic resistance in critically ill patients. Crit Care Med 2009; 37: Suppl. 10, S398-S399.
65. Clark MG, Rattigan S, Barrett EJ. Nutritive blood flow as an essential element supporting muscle anabolism. Curr Opin Clin Nutr Metab Care 2006; 9: 185-189. (Pubitemid 44097826)
66. Ahlbeck K, Fredriksson K, Rooyackers O, et al. Signs of critical illness polyneuropathy and myopathy can be seen early in the ICU course. Acta Anaesthesiol Scand 2009; 53: 717-723.
67. Leon A, Boczkowski J, Dureuil B, et al. Effects of endotoxic shock on diaphragmatic function in mechanically ventilated rats. J Appl Physiol 1992; 72: 1466-1472.
68. Lanone S, Taille C, Boczkowski J, et al. Diaphragmatic fatigue during sepsis and septic shock. Intensive Care Med 2005; 31: 1611-1617. (Pubitemid 41679356)
69. Supinski G, Nethery D, Stofan D, et al. Comparison of the effects of endotoxin on limb, respiratory, and cardiac muscles. J Appl Physiol 1996; 81: 1370-1378. (Pubitemid 26309150)
70. Supinski GS, Callahan LA. Caspase activation contributes to endotoxin-induced diaphragm weakness. J Appl Physiol 2006; 100: 1770-1777. (Pubitemid 43845849)
71. Polkey MI, Moxham J. Clinical aspects of respiratory muscle dysfunction in the critically ill. Chest 2001; 119: 926-939. (Pubitemid 32197668)
72. Bolton C, Gilbert J, Hahn A, et al. Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychiatry 1984; 47: 1223-1231. (Pubitemid 15204538)
73. Massa R, Carpenter S, Holland P, et al. Loss and renewal of thick myofilaments in glucocorticoid-treated rat soleus after denervation and reinnervation. Muscle Nerve 1992; 15: 1290-1298.
74. Jaber S, Jung B, Matecki S, et al. Clinical review: ventilator-induced diaphragmatic dysfunction - human studies confirm animal model findings!. Crit Care 2011; 15: 206.
75. Polkey MI, Duguet A, Luo Y, et al. Anterior magnetic phrenic nerve stimulation: laboratory and clinical evaluation. Intensive Care Med 2000; 26: 1065-1075.
76. Mills GH, Ponte J, Hamnegard CH, et al. Tracheal tube pressure change during magnetic stimulation of the phrenic nerves as an indicator of diaphragm strength on the intensive care unit. Br J Anaesth 2001; 87: 876-884. (Pubitemid 33130279)
77. Hermans G, Agten A, Testelmans D, et al. Increased duration of mechanical ventilation is associated with decreased diaphragmatic force: a prospective observational study. Crit Care 2011; 14: R127.
78. Jung B, Constantin JM, Rossel N, et al. Adaptive support ventilation prevents ventilator-induced diaphragmatic dysfunction in piglet: an in vivo and in vitro study. Anesthesiology 2011; 112: 1435-1443.
79. Gayan-Ramirez G, Testelmans D, Maes K, et al. Intermittent spontaneous breathing protects the rat diaphragm from mechanical ventilation effects. Crit Care Med 2005; 33: 2804-2809. (Pubitemid 41816415)
80. Reid MB, Lannergren J, Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-α: involvement of muscle myofilaments. Am J Respir Crit Care Med 2002; 166: 479-484.
81. Smith IJ, Lecker SH, Hasselgren PO. Calpain activity and muscle wasting in sepsis. Am J Physiol Endocrinol Metab 2008; 295: E762-E771.
82. Callahan LA, Supinski GS. Sepsis-induced myopathy. Crit Care Med 2009; 37: Suppl. 10, S354-S367.
83. Bartoli M, Richard I. Calpains in muscle wasting. Int J Biochem Cell Biol 2005; 37: 2115-2133. (Pubitemid 41206825)
84. Stockholm D, Herasse M, Marchand S, et al. Calpain 3 mRNA expression in mice after denervation and during muscle regeneration. Am J Physiol Cell Physiol 2001; 280: C1561-C1569.
85. Williams AB, Decourten-Myers GM, Fischer JE, et al. Sepsis stimulates release of myofilaments in skeletal muscle by a calcium-dependent mechanism. FASEB J 1999; 13: 1435-1443. (Pubitemid 29382511)
86. Benson DW, Hasselgren PO, Hiyama DT, et al. Effect of sepsis on calcium uptake and content in skeletal muscle and regulation in vitro by calcium of total and myofibrillar protein breakdown in control and septic muscle: results from a preliminary study. Surgery 1989; 106: 87-93. (Pubitemid 19186192)
87. Smith IJ, Dodd SL. Calpain activation causes a proteasome-dependent increase in protein degradation and inhibits the Akt signalling pathway in rat diaphragm muscle. Exp Physiol 2007; 92: 561-573. (Pubitemid 46608406)
88. Supinski GS, Callahan LA. Calpain activation contributes to endotoxin-induced diaphragmatic dysfunction. Am J Respir Cell Mol Biol 2010; 42: 80-87.
89. Supinski GS, Wang W, Callahan LA. Caspase and calpain activation both contribute to sepsis-induced diaphragmatic weakness. J Appl Physiol 2009; 107: 1389-1396.
90. Liu SH, Lai JL, Yang RS, et al. Nitric oxide is not involved in the endotoxemia-induced alterations in Ca2+ and ryanodine responses in mouse diaphragms. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 327-334.
91. Zink W, Kaess M, Hofer S, et al. Alterations in intracellular Ca2+-homeostasis of skeletal muscle fibers during sepsis. Crit Care Med 2008; 36: 1559-1563. (Pubitemid 351620665)
92. Friedrich O, Hund E, Weber C, et al. Critical illness myopathy serum fractions affect membrane excitability and intracellular calcium release in mammalian skeletal muscle. J Neurol 2004; 251: 53-65. (Pubitemid 38210490)
93. Z'Graggen W, Lin C, Howard R, et al. Nerve excitability changes in critical illness polyneuropathy. Brain 2006; 129: 2461-2470.
94. Rich MM, Teener JWT, Raps EC, et al. Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology 1996; 46: 731-736. (Pubitemid 26099640)
95. Lefaucheur JP, Nordine T, Rodriguez P, et al. Origin of ICU acquired paresis determined by direct muscle stimulation. J Neurol Neurosurg Psychiatry 2006; 77: 500-506.
96. Latronico N, Fenzi F, Recupero D, et al. Critical illness myopathy and neuropathy. Lancet 1996; 347: 1579-1582. (Pubitemid 26170874)
97. Druschky A, Herkert M, Radespiel-Tröger M, et al. Critical illness polyneuropathy: clinical findings and cell culture assay of neurotoxicity assessed by a prospective study. Intensive Care Med 2001; 27: 686-693. (Pubitemid 32318330)
98. Hermans G, De Jonghe B, Bruyninckx F, et al. Clinical review: critical illness polyneuropathy and myopathy. Crit Care 2008; 12: 238.
99. Rich MM, McGarvey ML, Teener JW, et al. ECG changes during septic shock. Cardiology 2002; 97: 187-196.
100. Rich M, Pinter M, Kraner S, et al. Loss of electrical excitability in an animal model of acute quadriplegic myopathy. Ann Neurol 1998; 43: 171-179. (Pubitemid 28110119)
101. Lin MC, Ebihara S, El Dwairi Q, et al. Diaphragm sarcolemmal injury is induced by sepsis and alleviated by nitric oxide synthase inhibition. Am J Respir Crit Care Med 1998; 158: 1656-1663.
102. Teener JW, Rich MM, Dysregulation of sodium channel gating in critical illness myopathy. J Muscle Res Cell Motil 2006; 27: 291-296. (Pubitemid 44325608)
103. Rossignol B, Gueret G, Pennec JP, et al. Effects of chronic sepsis on the voltage-gated sodium channel in isolated rat muscle fibers. Crit Care Med 2007; 35: 351-357. (Pubitemid 46148521)
104. Haeseler G, Foadi N, Wiegand E, et al. Endotoxin reduces availability of voltage-gated human skeletal muscle sodium channels at depolarized membrane potentials. Crit Care Med 2008; 36: 1239-1247. (Pubitemid 351482674)
105. Friedrich O. Critical illness myopathy: what is happening? Curr Opin Clin Nutr Metab Care 2006; 9: 403-409. (Pubitemid 44097810)
106. Caquelard F, Burnet H, Tagliarini F, et al. Effects of prolonged hypobaric hypoxia on human skeletal muscle function and electromyographic events. Clin Sci (Lond) 2000; 98: 329-337. (Pubitemid 30145240)
107. Hoppeler H, Kleinert E, Schlegel C, et al. Morphological adaptations of human skeletal muscle to chronic hypoxia. Int J Sports Med 1990; 11: Suppl. 1, S3-S9. (Pubitemid 20120060)
108. Gosker HR, van Mameren H, van Dijk PJ, et al. Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 617-625. (Pubitemid 34285157)
109. Vianna LG, Koulouris N, Lanigan C, et al. Effect of acute hypercapnia on limb muscle contractility in humans. J Appl Physiol 1990; 69: 1486-1493. (Pubitemid 20361272)
110. Juan G, Calverley P, Talamo C, et al. Effect of carbon dioxide on diaphragmatic function in human beings. N Engl J Med 1984; 310: 874-879. (Pubitemid 14173179)
111. Rafferty GF, Lou Harris M, Polkey MI, et al. Effect of hypercapnia on maximal voluntary ventilation and diaphragm fatigue in normal humans. Am J Respir Crit Care Med 1999; 160: 1567-1571.
112. Callahan LA, Stofan DA, Szweda LI, et al. Free radicals alter maximal diaphragmatic mitochondrial oxygen consumption in endotoxin-induced sepsis. Free Radic Biol Med 2001; 30: 129-138. (Pubitemid 32008096)
113. Boczkowski J, Lisdero CL, Lanone S, et al. Endogenous peroxynitrite mediates mitochondrial dysfunction in rat diaphragm during endotoxemia. FASEB J 1999; 13: 1637-1646.
114. Callahan LA, Supinski GS. Sepsis induces diaphragm electron transport chain dysfunction and protein depletion. Am J Respir Crit Care Med 2005; 172: 861-868. (Pubitemid 41369070)
115. Callahan LA, Supinski GS. Downregulation of diaphragm electron transport chain and glycolytic enzyme gene expression in sepsis. J Appl Physiol 2005; 99: 1120-1126. (Pubitemid 41214531)
116. Brealey D, Karyampudi S, Jacques TS, et al. Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure. Am J Physiol Regul Integr Comp Physiol 2004; 286: R491-R497. (Pubitemid 38252613)
117. Fredriksson K, Tjader I, Keller P, et al. Dysregulation of mitochondrial dynamics and the muscle transcriptome in ICU patients suffering from sepsis induced multiple organ failure. PLoS One 2008; 3: e3686.
118. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002; 360: 219-223. (Pubitemid 34804650)
119. Vanhorebeek I, De Vos R, Mesotten D, et al. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet 2005; 365: 53-59. (Pubitemid 40082146)
120. Fareed MU, Evenson AR, Wei W, et al. Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression. Am J Physiol Regul Integr Comp Physiol 2006; 290: R1589-R1597. (Pubitemid 43830824)
121. Li YP, Chen Y, Li AS, et al. Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes. Am J Physiol Cell Physiol 2003; 285: C806-C812. (Pubitemid 37158805)
122. Shang F, Gong X, Taylor A. Activity of ubiquitin-dependent pathway in response to oxidative stress. Ubiquitin-activating enzyme is transiently up-regulated. J Biol Chem 1997; 272: 23086-23093. (Pubitemid 27392436)
123. Pickering AM, Koop AL, Teoh CY, et al. The immunoproteasome, the 20S proteasome and the PA28ab proteasome regulator are oxidative-stress-adaptive proteolytic complexes. Biochem J 2010; 432: 585-594.
124. McClung JM, Judge AR, Talbert EE, et al. Calpain-1 is required for hydrogen peroxide-induced myotube atrophy. Am J Physiol Cell Physiol 2009; 296: C363-C371.
125. Jiang B, Xiao W, Shi Y, et al. Role of Smac/DIABLO in hydrogen peroxide-induced apoptosis in C2C12 myogenic cells. Free Radic Biol Med 2005; 39: 658-667. (Pubitemid 41112107)
126. Supinski GS, Callahan LA. Free radical-mediated skeletal muscle dysfunction in inflammatory conditions. J Appl Physiol 2007; 102: 2056-2063. (Pubitemid 46701978)
127. Reid MB, Andrade FH, Balke CW, et al. Redox mechanisms of muscle dysfunction in inflammatory disease. Phys Med Rehabil Clin N Am 2005; 16: 925-949. (Pubitemid 41415696)
128. Javesghani D, Magder SA, Barreiro E, et al. Molecular characterization of a superoxide-generating NAD(P)H oxidase in the ventilatory muscles. Am J Respir Crit Care Med 2002; 165: 412-418. (Pubitemid 34118518)
129. Boveris A, Alvarez S, Navarro A, The role of mitochondrial nitric oxide synthase in inflammation and septic shock. Free Radic Biol Med 2002; 33: 1186-1193. (Pubitemid 35246586)
130. Buck M, Chojkier M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J 1996; 15: 1753-1765. (Pubitemid 26119211)
131. Supinski G, Nethery D, Nosek TM, et al. Endotoxin administration alters the force vs. pCa relationship of skeletal muscle fibers. Am J Physiol Regul Integr Comp Physiol 2000; 278: R891-R896. (Pubitemid 30215201)
132. Bonetto A, Penna F, Muscaritoli M, et al. Are antioxidants useful for treating skeletal muscle atrophy? Free Radic Biol Med 2009; 47: 906-916.
133. Van den Berghe G, Schoonheydt K, Becx P, et al. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 2005; 64: 1348-1353. (Pubitemid 40570499)
134. Hermans G, Wilmer A, Meersseman W, et al. Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. Am J Respir Crit Care Med 2007; 175: 480-489. (Pubitemid 46354252)
135. Gore DC, Wolf SE, Sanford AP, et al. Extremity hyperinsulinemia stimulates muscle protein synthesis in severely injured patients. Am J Physiol Endocrinol Metab 2004; 286: E529-E534. (Pubitemid 38374949)
136. Cleveland BM, Weber GM. Effects of insulin-like growth factor-I, insulin, and leucine on protein turnover and ubiquitin ligase expression in rainbow trout primary myocytes. Am J Physiol Regul Integr Comp Physiol 2010; 298: R341-R350.
137. Hansen TK, Thiel S, Wouters PJ, et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 2003; 88: 1082-1088. (Pubitemid 36337759)
138. Mesotten D, Swinnen JV, Vanderhoydonc F, et al. Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocrinol Metab 2004; 89: 219-226. (Pubitemid 38183885)
139. Ishii DN, Lupien SB. Insulin-like growth factors protect against diabetic neuropathy: effects on sensory nerve regeneration in rats. J Neurosci Res 1995; 40: 138-144.
140. Biolo G, De Cicco M, Lorenzon S, et al. Treating hyperglycemia improves skeletal muscle protein metabolism in cancer patients after major surgery. Crit Care Med 2008; 36: 1768-1775.
141. Jespersen JG, Nedergaard A, Reitelseder S, et al. Activated protein synthesis and suppressed protein breakdown signaling in skeletal muscle of critically ill patients. PLoS One 2011; 6: e18090.
142. De Jonghe B, Sharshar T, Hopkinson N, et al. Paresis following mechanical ventilation. Curr Opin Crit Care 2004; 10: 47-52. (Pubitemid 38183924)
143. Berg H, Larsson L, Tesch P. Lower limb skeletal muscle function after 6 wk of bed rest. J Appl Physiol 1997; 82: 182-188. (Pubitemid 27052059)
144. Fink H, Helming M, Unterbuchner C, et al. Systemic inflammatory response syndrome increases immobility-induced neuromuscular weakness. Crit Care Med 2008; 36: 910-916.
145. Lawler JM, Song W, Demaree SR. Hindlimb unloading increases oxidative stress and disrupts antioxidant capacity in skeletal muscle. Free Radic Biol Med 2003; 35: 9-16. (Pubitemid 36782333)
146. Enns DL, Raastad T, Ugelstad I, et al. Calpain/calpastatin activities and substrate depletion patterns during hindlimb unweighting and reweighting in skeletal muscle. Eur J Appl Physiol 2007; 100: 445-455. (Pubitemid 46773994)
147. Sandri M. Apoptotic signaling in skeletal muscle fibers during atrophy. Curr Opin Clin Nutr Metab Care 2002; 5: 249-253. (Pubitemid 40684669)
148. Siu PM, Pistilli EE, Alway SE. Apoptotic responses to hindlimb suspension in gastrocnemius muscles from young adult and aged rats. Am J Physiol Regul Integr Comp Physiol 2005; 289: R1015-R1026. (Pubitemid 41397049)
149. Fan E, Zanni J, Dennison C, et al. Critical illness neuromyopathy and muscle weakness in patients in the intensive care unit. AACN Adv Crit Care, 20: 243-253.
150. Murray M, Brull S, Bolton C. Brief review: nondepolarizing neuromuscular blocking drugs and critical illness myopathy. Can J Anaesth 2006; 53: 1148-1156. (Pubitemid 44756161)
151. Fan E. What is stopping us from early mobility in the intensive care unit? Crit Care Med 2010; 38: 2254-2255.
152. Morris PE, Griffin L, Berry M, et al. Receiving early mobility during an intensive care unit admission is a predictor of improved outcomes in acute respiratory failure. Am J Med Sci 2011; 341: 373-377.
153. Strasser EM, Stattner S, Karner J, et al. Neuromuscular electrical stimulation reduces skeletal muscle protein degradation and stimulates insulin-like growth factors in an age- and current-dependent manner: a randomized, controlled clinical trial in major abdominal surgical patients. Ann Surg 2009; 249: 738-743.
154. Routsi C, Gerovasili V, Vasileiadis I, et al. Electrical muscle stimulation prevents critical illness polyneuromyopathy: a randomized parallel intervention trial. Crit Care 2010; 14: R74.
155. Haidet AM, Rizo L, Handy C, et al. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci USA 2008; 105: 4318-4322. (Pubitemid 351754378)
156. Hermans G, De Jonghe B, Bruyninckx F, et al. Interventions for preventing critical illness polyneuropathy and critical illness myopathy. Cochrane Database Syst Rev 2009; 1: CD006832.